ERIS Lifesciences Ltd
About
ERIS Lifesciences Limited is a pharmaceutical company specializing in the manufacturing and marketing of branded formulations, primarily targeting chronic and lifestyle-related therapies. With a strong focus on cardiology, diabetology, neurology, and gastroenterology, ERIS caters to the growing demand for specialized healthcare solutions in India. The company emphasizes innovation, quality, and doctor-driven prescription sales, distinguishing itself in a competitive pharmaceutical landscape. ERIS has expanded its product portfolio through strategic acquisitions and research-driven developments, ensuring a strong presence in both acute and chronic segments. Its commitment to patient-centric healthcare and medical advancements drives its growth in the Indian pharmaceutical market.
Featured In Fortune India Ranking
Financial Data 2024
Financial Data
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (INR Cr) | 2079 19.5% | 1740 26.7% | 1374 9.2% | 1259 17.9% | 1068 4.0% | 1027 16.1% | 885 13.8% | 778 31.2% | 593 5.9% | 560 9.9% | 509 22.4% | 416 48.5% | 280 - |
| Net Operating Income (INR Cr) | 2056 18.68% | 1733 28.63% | 1347 11.15% | 1212 12.83% | 1074 9.36% | 982 14.79% | 856 14.16% | 750 25.54% | 597 9.43% | 546 7.22% | 509 29.45% | 393 43.48% | 274 0.00% |
| Profit (INR Cr) | 392 2.6% | 382 -5.9% | 406 14.4% | 355 19.8% | 297 2.0% | 291 -1.1% | 294 19.2% | 247 84.8% | 134 49.7% | 89 26.7% | 70 21.0% | 58 57.6% | 37 - |
| Assets (INR Cr) | 6064 91.9% | 3160 55.6% | 2030 25.3% | 1621 21.2% | 1337 -2.6% | 1373 6.8% | 1285 108.5% | 616 87.6% | 329 12.5% | 292 46.3% | 199 53.1% | 130 88.8% | 69 - |
| Net Worth (INR Cr) | 2586 17.8% | 2196 15.1% | 1908 21.1% | 1576 21.6% | 1296 12.7% | 1151 33.6% | 861 51.9% | 567 89.5% | 299 12.6% | 266 50.5% | 177 66.4% | 106 121.5% | 48 0.0% |
| Employee Cost (INR Cr) | 404 16.7% | 346 38.4% | 250 9.1% | 229 11.5% | 206 7.9% | 191 21.2% | 157 19.9% | 131 5.3% | 125 -0.8% | 126 38.8% | 91 34.5% | 67 56.6% | 43 - |
| Interest Cost (INR Cr) | 85 | 26 | 4 | 2 | 2 | 23 | 11 | 1 | 0 | 0 | 0 | 1 | 1 |
| Cash & Bank Balance (INR Cr) | 1401 | 58 | 52 | 38 | 67 | 8 | 11 | 2 | 10 | 6 | 7 | 5 | 9 |
| Total Debt (INR Cr) | 2781 | 877 | 84 | 7 | 0 | 176 | 377 | 1 | 1 | 1 | 1 | 3 | 5 |
Key Financial Ratios
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profit As % Of Revenues | 18.9% | 22.0% | 29.6% | 28.2% | 27.8% | 28.3% | 33.2% | 31.7% | 22.5% | 15.9% | 13.8% | 14.0% | 13.2% |
| Profit As % Of Assets | 6.5% | 12.1% | 20.0% | 21.9% | 22.2% | 21.2% | 22.9% | 40.0% | 40.7% | 30.6% | 35.3% | 44.7% | 53.5% |
| Profit As % Of Networth | 15.2% | 17.4% | 21.3% | 22.5% | 22.9% | 25.3% | 34.2% | 43.5% | 44.6% | 33.6% | 39.9% | 54.9% | 77.1% |
| Interest Cost to EBITDA % | 12.6% | 4.9% | 0.9% | 0.5% | 0.6% | 6.7% | 3.3% | 0.4% | 0.2% | 0.0% | 0.3% | 0.9% | 2.0% |
| Debt to Equity Ratio | 1.08 | 0.40 | 0.04 | 0.00 | - | 0.15 | 0.44 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.10 |
| RONW | 16.6% | 18.2% | 23.3% | 24.7% | 24.2% | 28.9% | 41.3% | 56.9% | 47.7% | 40.4% | 49.9% | 75.9% | 77.4% |
| ROCE | 12.1% | 16.7% | 24.5% | 26.8% | 24.8% | 26.0% | 34.9% | 59.2% | 50.5% | 45.3% | 61.5% | 88.6% | 88.6% |